Evaluation of the efficacy of adagrasiib in patients with advanced cancer

KRAS gene mutations have long been a focus and problem in cancer research. As one of the common "driver genes" in cancer, mutations in KRAS can promote the continuous proliferation and metastasis of cancer cells, posing a great threat to patients' lives. Adagrasib, a KRAS G12C inhibitor, precisely inhibits the activity of KRAS G12C and blocks the conduction of key signaling pathways in cancer cells, thus curbing the rampant growth of cancer cells.

Non-small cell lung cancer is one of the most common types of lung cancer, and KRAS gene mutations are very common in NSCLC, accounting for about 25% of KRAS mutated lung cancers. KRAS G12C mutation is one of the most common types of mutations in the KRAS gene, which leads to abnormal proliferation and viability of tumor cells. Early clinical trial results show that adagrasib has a significant therapeutic effect in some NSCLC patients. A clinical trial called CodeBreaK 100 found that approximately 45% of patients with KRAS G12C mutation-positive NSCLC experienced tumor shrinkage after treatment with adagrasib. This result demonstrates that adagrasib can effectively inhibit tumor growth and progression.

Although adagrasib has shown good therapeutic effects, it should be noted that not allNSCLC patients are suitable for treatment with this drug. Adagrasiib is mainly suitable for patients who are positive for the KRAS G12C mutation, so genetic testing should be performed before use to determine whether the patient is suitable for this treatment. In addition, the side effects of adagrasiib are relatively minor and controllable. Most patients only experience mild adverse reactions during treatment, such as mild fatigue, gastrointestinal discomfort, etc. These reactions can usually be effectively alleviated by adjusting the medication regimen or adjuvant treatment, and have limited impact on the patient's quality of life.